Table 1. Major clinical variables before and during TKI-rotation therapy.
| PO-BOmonths* | WBC G/L | PLTG/L | % blasts | BMFibrosis | LDHU/L | BCR-ABL1% in PB cells** | % Ph+ cellsin BM samples | |
|---|---|---|---|---|---|---|---|---|
| PB | BM | |||||||
| −18 | 04.82 | 235 | 00 | nd | yes | 292 | 26.463 | 80 |
| −15 | 03.65 | 222 | 00 | nd | nd | 374 | 28.283 | nd |
| −12 | 04.01 | 123 | 00 | nd | nd | 321 | 11.548 | nd |
| −09 | 04.29 | 101 | 01 | nd | nd | 339 | 29.549 | nd |
| −06 | 04.77 | 099 | 02 | nd | nd | 382 | 52.293 | nd |
| −03 | 05.12 | 129 | 02 | nd | nd | 504 | 64.341 | nd |
| −01 | 08.11 | 154 | 23 | 32 | nd | 714 | 86.000 | 100 |
| 00 | 24.41 | 088 | 36 | nd | nd | 1,033 | 56.480 | nd |
| +01 | 08.93 | 046 | 02 | nd | nd | 552 | 36.573 | nd |
| +03 | 04.93 | 008 | 00 | nd | nd | 472 | 0.026 | nd |
| +06 | 05.49 | 027 | 00 | nd | nd | 579 | 0.011 | nd |
| +09 | 06.18 | 059 | 01 | nd | nd | 338 | 0.023 | nd |
| +12 | 05.29 | 070 | 00 | nd | nd | 316 | 0.036 | nd |
| +15 | 06.68 | 080 | 00 | nd | nd | 230 | 0.573 | nd |
| +18 | 07.67 | 131 | 00 | < 5 | no | 230 | < 0.0032 | nd |
| +21 | 07.80 | 110 | 00 | nd | nd | 206 | < 0.0032 | nd |
| +24 | 08.95 | 126 | 00 | nd | nd | 215 | < 0.0032 | nd |
| +27 | 10.99 | 164 | 00 | nd | nd | 242 | < 0.0032 | nd |
| +30 | 10.09 | 175 | 00 | nd | nd | 263 | < 0.0032 | nd |
| +33 | 07.30 | 131 | 00 | nd | nd | 231 | < 0.0032 | nd |
| +36 | 07.39 | 189 | 00 | nd | nd | 278 | < 0.0032 | nd |
Abbreviations: PO, ponatinib; BO, bosutinib; PLT, platelet count; PB, peripheral blood; BM, bone marrow; LDH, lactate dehydrogenase; nd, not done.
*Months before or after the start of ponatinib-bosutinib rotation therapy.
**BCR-ABL1 mRNA levels were determined by qPCR and expressed as percent of ABL1 after adjusting to the international scale (IS).